GlassScriptPhysician profile
Andi Qipo
NPI 1164768461
$1,528.38
in general payments reported to CMS, 2019-2025
20 companies · $554 in 2025
The $554 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $104 · 2023: $276 · 2024: $594 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $469.42 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.62 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $150.27 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $133.76 | 2024-2025 | Veozah |
| Pfizer INC. | $79.79 | 2022-2024 | |
| Glaxosmithkline, LLC. | $71.09 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $70.25 | 2022-2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $63.60 | 2024-2025 | Minimed 780g |
| Teva Pharmaceuticals USA, INC. | $51.27 | 2024-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $47.23 | 2024-2025 | Farxiga, Airsupra |
| Inspire Medical Systems, INC. | $27.14 | 2024 | Inspire |
| Abbott Laboratories | $24.18 | 2025 | Freestyle Libre 3 |
| Alvogen INC | $19.95 | 2024 | Teriparatide |
| Renalytix Ai, INC. | $19.90 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Scpharmaceuticals INC. | $18.20 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $17.55 | 2025 | Ibsrela |
| Amgen INC. | $15.51 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.34 | 2024 | Gvoke Hypopen |
| Actelion Pharmaceuticals US, INC. | $15.00 | 2023 | Opsumit, Uptravi |
| Abbvie INC. | $13.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andi Qipo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.